Respiratory Infections

Pfizer indicates their RSV vaccine candidate, Abrysvo (RSVpreF), to prevent acute respiratory disease and lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years and older by active immunization.

Two people developed Guillain-Barre syndrome among a total of 19,942 vaccinated participants in the clinical studies submitted for the company’s biologicals license application (BLA).

The Lucira COVID-19 & Flu Test is a single-use at-home test kit that provides results from self-collected nasal swab samples in roughly 30 minutes.

Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.

Experts address patient hesitancy around both COVID-19 and influenza vaccines.

The federal agency set a Prescription Drug User Fee Act (PDUFA) action date of August 2023.

Jacinda Abdul-Mutakabbir, PharmD, comments on building trust with community members and educating people about respiratory infection vaccines.

Experts share their approach to encouraging patients with symptoms of respiratory infections to get tested and vaccinated, and how that helps to control the spread of sickness.

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, and Jacinda Abdul-Mutakabbir, PharmD, discuss what both the clinician and the patient need to know about testing for respiratory viruses.

Priya Nori, MD, comments on the use of at-home tests for respiratory disease, including for COVID-19 and influenza.

The candidate, Ad26.RSV.preF–RSV preF protein vaccine, was 80.0% effective against severe disease and 69.8% effective against any RSV acute respiratory infection.

Why have “long COVID” cases become less frequent and less severe over time?

Jacinda Abdul-Mutakabbir, PharmD, examines the mechanisms of action of the different respiratory viral infection tests.

Experts review testing recommendations for respiratory viral infections and the types of testing options available.

Spherical hydrogel inhalation for enhanced lung defense (SHIELD) is an investigational inhalable that coats the airways and serves as a physical barrier against COVID-19.

Infectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.

Expert panelists continue the discussion of treatment for patients with coinfection of respiratory diseases.

Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, comment on the overlap of respiratory infections and their approach to getting people treatment.

New research suggests the majority of people hospitalized with influenza also had a chronic illness.

Can a similar approach that brought breakthrough therapies for cystic fibrosis bring about much needed change to antibiotic development?

The vast majority of COVID-19 infections are diagnosed at home, with rapid antigen tests. How has this affected public reports of COVID-19 prevalence?

University of Missouri investigators found people experiencing post-acute sequelae of COVID-19 (long COVID) are susceptible to developing 7 health defects in the year following infection.

The designation was based on positive top line data from the ConquerRSV phase 3 efficacy trial.

COVID-19 mortalities tend to be lowest in children, but the virus is still the #8 cause of death in children and young people 0-19 years old.

Experts provide an overview of the clinical presentations of respiratory infections such as COVID-19, influenza, and respiratory syncytial virus.